Curative Oncology Biosimilars
Addressing Knowledge Gaps In The Use Of Curative Oncology Biosimilars Across Europe
The World Health Organization (WHO) has predicted that annual cancer cases will rise from 14 million in 2012 to 22 million within the next two decades. Indeed, in the UK alone Macmillan cancer support estimate there will be 4 million people living with cancer. These statistics demonstrate the enormous need to provide cancer treatment and resources to meet the growing incidence, in low resource countries. Biosimilars due to the reduced cost but equivalent efficacy is likely to be popular throughout Europe.
Nurses are at the front line of cancer care and treatment
As the largest group of health care professionals in the world, with an estimated 17 million nurses worldwide, nurses are in an ideal position to educate patients and caregivers through a partnership approach and individualized care where possible.
Why is this programme necessary?
It is apparent that there are gaps in nurses’ skills in understanding, delivering, teaching, and supporting patients and caregivers (ref) receiving biosimilars as a class of treatment. Despite these drugs being used within many cancer treatment settings, the educational resources for patients and their caregivers creating awareness about these therapies, are minimal – hence, a significant and growing need exists for educational resources designed for patients and their caregivers to ensure they understand biosimilars as a class of treatment.
Education for nurses in Europe remains limited and cancer treatment education focuses mainly on more established chemotherapeutic agents. The increasing use of biosimilars means nurses require additional knowledge and skills about the profile, indications, and side effects of these drugs to provide assistance, support and education to patients and their caregivers.
This European Train-the-Trainer Programme focuses on the educational needs of nurses in order to understand the implications of biosimilars drug development, their potential for treating and curing cancers, administration, side effect profiles and education requirements.
The creation and dissemination of these training modules was made possible through a grant from Pfizer.
PLEASE NOTE: the purpose of this program was to develop training modules for European Cancer Nurses. Since this program was delivered virtually and being made available online, access is open to any oncology nurse leaders from any region.
Host A Workshop
Are you interested in hosting a training session on the use of Curative Oncology Biosimilars? Materials are available in different languages for your convenience below.
Steering Group Members
ISNCC would like to acknowledge the work of the steering group members in developing this training program and package on Addressing Knowledge Gaps In The Use Of Curative Oncology Biosimilars:
Virtual presentation and live Q&A with Dr. Elaine Tomlins held on May 27, 2021
The purpose of this programme is to provide training materials and resources to nurse leaders in order to achieve the following aims in their region:
Host a Curative Oncology Biosimilars program in your country by downloading the training materials below.DOWNLOAD English Modules & Templates